Copy to clipboard 
DePuy Synthes reported 3Q19 orthopedic revenue of USD $2,137MM, +1.2% vs. 3Q18.
- Price pressure modestly improved compared to 2Q19, but still negative across all segments with spine, hips and trauma declining 2% and knees declining 1%
- Continued strength for ACTIS hip stem and KINCISE automated surgical system, as well as leadership in the anterior surgical approach
- Double-digit knee growth in ex-U.S. markets driven by ATTUNE Revision and offset by competitive pressure in the U.S.; within the quarter, the ATTUNE Cementless was launched in the U.S. market
- Trauma gains driven by market growth and uptake of new products, such as the Femoral Neck System and Femoral Recon Nail; sales growth aided by one-time rebate reserve adjustment in the U.S.
- Spine declines occurred primarily in the U.S.; newer products such as the VIPER PRIME system and CONDUIT interbody platform couldn’t offset share loss in the quarter
- Partnership with Anika Therapeutics for MONOVISC and ORTHOVISC drove U.S. orthobiologics growth
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $799.9 | $790.1 | $9.8 | 1.2% |
| Knees | $352.8 | $348.9 | $3.9 | 1.1% |
| Hips | $344.8 | $337.9 | $6.9 | 2% |
| Extremities | $102.3 | $103.4 | ($1.1) | (1%) |
| Spine | $342.1 | $352.7 | ($10.6) | (3%) |
| Trauma | $648.8 | $625.5 | $23.3 | 3.7% |
| Sports Medicine | $162.6 | $157.2 | $5.4 | 3.5% |
| Orthobiologics | $97.3 | $98.3 | ($1.0) | (1%) |
| Other (CMF) | $86.4 | $87.2 | ($0.9) | (1%) |
| Total | $2,137.0 | $2,111.0 | $26.0 | 1.2% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $2,507.2 | $2,531.9 | ($24.7) | (1%) |
| Knees | $1,108.8 | $1,134.4 | ($25.5) | (2.2%) |
| Hips | $1,084.8 | $1,077.4 | $7.5 | 0.7% |
| Extremities | $313.5 | $320.2 | ($6.7) | (2.1%) |
| Spine | $1,062.8 | $1,092.7 | ($29.9) | (2.7%) |
| Trauma | $1,947.6 | $1,936.7 | $10.8 | 0.6% |
| Sports Medicine | $483.8 | $487.0 | ($3.2) | (0.7%) |
| Orthobiologics | $298.0 | $304.4 | ($6.4) | (2.1%) |
| Other (CMF) | $264.6 | $270.3 | ($5.7) | (2.1%) |
| Total | $6,564.0 | $6,623.0 | ($59.0) | (0.9%) |
ORTHOWORLD estimates orthopedic sales by geographic region as follows ($MM).
| Geographic Region | 3Q19 | 3Q18 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,300.0 | $1,284.0 | $16.0 | 1.2% |
| Ex-US | $837.0 | $827.0 | $10.0 | 1.2% |
| EMEA | $376.7 | $372.2 | $4.5 | 1.2% |
| Asia Pacific | $297.1 | $289.5 | $7.7 | 2.7% |
| Rest of World | $163.2 | $165.4 | ($2.2) | (1.3%) |
| Total | $2,137.0 | $2,111.0 | $26.0 | 1.2% |
Net earnings for all Johnson & Johnson revenue are as follows.
| Amt | % of Sales | |
|---|---|---|
| Sales | $20,729.0 | |
| Cost of Sales | ($6,867.0) | 33.1% |
| Selling and Admin | ($5,374.0) | 25.9% |
| R & D | ($2,599.0) | 12.5% |
| Other | ($1,056.0) | 5.1% |
| Net Earnings | $4,833.0 | 23.3% |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
DePuy Synthes reported 3Q19 orthopedic revenue of USD $2,137MM, +1.2% vs. 3Q18.
Price pressure modestly improved compared to 2Q19, but still negative across all segments with spine, hips and trauma declining 2% and knees declining 1%
Continued strength for ACTIS hip stem and KINCISE automated surgical system, as well as leadership...
DePuy Synthes reported 3Q19 orthopedic revenue of USD $2,137MM, +1.2% vs. 3Q18.
- Price pressure modestly improved compared to 2Q19, but still negative across all segments with spine, hips and trauma declining 2% and knees declining 1%
- Continued strength for ACTIS hip stem and KINCISE automated surgical system, as well as leadership in the anterior surgical approach
- Double-digit knee growth in ex-U.S. markets driven by ATTUNE Revision and offset by competitive pressure in the U.S.; within the quarter, the ATTUNE Cementless was launched in the U.S. market
- Trauma gains driven by market growth and uptake of new products, such as the Femoral Neck System and Femoral Recon Nail; sales growth aided by one-time rebate reserve adjustment in the U.S.
- Spine declines occurred primarily in the U.S.; newer products such as the VIPER PRIME system and CONDUIT interbody platform couldn’t offset share loss in the quarter
- Partnership with Anika Therapeutics for MONOVISC and ORTHOVISC drove U.S. orthobiologics growth
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $799.9 | $790.1 | $9.8 | 1.2% |
| Knees | $352.8 | $348.9 | $3.9 | 1.1% |
| Hips | $344.8 | $337.9 | $6.9 | 2% |
| Extremities | $102.3 | $103.4 | ($1.1) | (1%) |
| Spine | $342.1 | $352.7 | ($10.6) | (3%) |
| Trauma | $648.8 | $625.5 | $23.3 | 3.7% |
| Sports Medicine | $162.6 | $157.2 | $5.4 | 3.5% |
| Orthobiologics | $97.3 | $98.3 | ($1.0) | (1%) |
| Other (CMF) | $86.4 | $87.2 | ($0.9) | (1%) |
| Total | $2,137.0 | $2,111.0 | $26.0 | 1.2% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $2,507.2 | $2,531.9 | ($24.7) | (1%) |
| Knees | $1,108.8 | $1,134.4 | ($25.5) | (2.2%) |
| Hips | $1,084.8 | $1,077.4 | $7.5 | 0.7% |
| Extremities | $313.5 | $320.2 | ($6.7) | (2.1%) |
| Spine | $1,062.8 | $1,092.7 | ($29.9) | (2.7%) |
| Trauma | $1,947.6 | $1,936.7 | $10.8 | 0.6% |
| Sports Medicine | $483.8 | $487.0 | ($3.2) | (0.7%) |
| Orthobiologics | $298.0 | $304.4 | ($6.4) | (2.1%) |
| Other (CMF) | $264.6 | $270.3 | ($5.7) | (2.1%) |
| Total | $6,564.0 | $6,623.0 | ($59.0) | (0.9%) |
ORTHOWORLD estimates orthopedic sales by geographic region as follows ($MM).
| Geographic Region | 3Q19 | 3Q18 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,300.0 | $1,284.0 | $16.0 | 1.2% |
| Ex-US | $837.0 | $827.0 | $10.0 | 1.2% |
| EMEA | $376.7 | $372.2 | $4.5 | 1.2% |
| Asia Pacific | $297.1 | $289.5 | $7.7 | 2.7% |
| Rest of World | $163.2 | $165.4 | ($2.2) | (1.3%) |
| Total | $2,137.0 | $2,111.0 | $26.0 | 1.2% |
Net earnings for all Johnson & Johnson revenue are as follows.
| Amt | % of Sales | |
|---|---|---|
| Sales | $20,729.0 | |
| Cost of Sales | ($6,867.0) | 33.1% |
| Selling and Admin | ($5,374.0) | 25.9% |
| R & D | ($2,599.0) | 12.5% |
| Other | ($1,056.0) | 5.1% |
| Net Earnings | $4,833.0 | 23.3% |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers Mike Evers is an analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
